静脉注射免疫球蛋白市场规模、份额和成长分析（按产品、通路、应用和地区划分）－2026-2033年产业预测

预计到 2024 年，静脉注射免疫球蛋白市场规模将达到 138.4 亿美元，到 2025 年将达到 148.5 亿美元，到 2033 年将达到 261 亿美元，预测期（2026-2033 年）的复合年增长率为 7.3%。

静脉注射免疫球蛋白（IVIG）市场正经历显着成长，这主要受多种因素影响，包括人口老化和免疫不全症盛行率上升。 IVIG疗法的广泛应用及其仿单标示外用药进一步推动了市场需求。慢性脱髓鞘多发性神经炎（CIDP）及相关出血性疾病患者数量的显着增加也强化了这一趋势。此外，医疗保健投资的不断增长也推动了该市场的发展。自体免疫疾病和其他各种疾病发病率的上升也在塑造IVIG市场格局中发挥关键作用，凸显了该产品在满足多样化医疗需求和应对复杂免疫健康挑战方面的重要作用。

静脉注射免疫球蛋白市场驱动因素

静脉注射免疫球蛋白疗法作为多种罕见免疫和神经系统疾病（尤其是原发性免疫力缺乏及相关疾病）的主要治疗方法，日益普及是推动市场成长的关键因素。静脉注射免疫球蛋白疗法作为主要治疗方案的广泛认可，凸显了其在应对这些复杂健康问题方面的有效性和重要性。随着越来越多的医疗服务提供者和患者认识到该治疗方法的益处，对静脉注射免疫球蛋白的需求持续增长，进一步巩固了其在治疗这些棘手疾病中的作用，并推动了市场的发展。

限制静脉注射免疫球蛋白市场的因素

诊断和治疗去髓鞘化疾病带来的经济负担对静脉注射免疫球蛋白（IVIG）市场构成重大挑战。尤其令人担忧的是IVIG治疗费用不断上涨，因为这种治疗通常需要每隔几週进行一次定期静脉输注，一年内可能需要多次治疗。 IVIG的平均成本估计约为每克73.89美元，累积费用可能高达每年约1万美元。如此高昂的费用严重阻碍了市场成长，限制了需要这种重要治疗以有效控制病情的患者获得治疗的机会。

静脉注射免疫球蛋白市场趋势

静脉注射免疫球蛋白（IVIG）市场正经历着动态变革，其成长潜力正受到关键趋势的驱动。其中一个显着趋势是IVIG在神经系统疾病治疗中的应用日益广泛，这标誌着其应用范围正从传统用途扩展到更广泛的领域。此外，将个人化医疗概念融入IVIG疗法标誌着一个变革性的转折点，使得针对个别患者情况的客製化治疗成为可能。同时，创新免疫调节疗法的兴起正在重塑市场格局，拓展治疗可能性，改善患者预后，进而推动IVIG产品的整体需求与发展。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球静脉注射免疫球蛋白市场规模（按产品和复合年增长率划分）（2026-2033 年）

• IGG
• IGA
• IGM
• IGE
• IGD

全球静脉注射免疫球蛋白市场规模（依通路划分）及复合年增长率（2026-2033 年）

• 医院药房
• 专科药房
• 其他的

全球静脉注射免疫球蛋白市场规模（按应用及复合年增长率划分）（2026-2033 年）

• 免疫力缺乏
• CIDP
• 低丙种球蛋白血症
• 先天性爱滋病
• 慢性淋巴性白血病
• 重症肌无力
• 多灶性运动神经病变
• ITP
• 川崎病
• Guillain-Barré二氏症候群
• 其他的

全球静脉注射免疫球蛋白市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• CSL Behring（Australia）
• Grifols, SA（Spain）
• Octapharma AG（Switzerland）
• Kedrion SpA（Italy）
• Bio Products Laboratory Ltd.（United Kingdom）
• Biotest AG（Germany）
• China Biologic Products Holdings, Inc.（China）
• LFB SA（France）
• Shanghai RAAS Blood Products Co., Ltd.（China）
• ADMA Biologics, Inc.（United States）
• Sanquin Blood Supply Foundation（Netherlands）
• Kamada Ltd.（Israel）
• Emergent BioSolutions Inc.（United States）
• Hualan Biological Engineering Inc.（China）
• Green Cross Corporation（South Korea）
• Bharat Serums and Vaccines Limited（India）
• Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.（China）
• Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.（China）
• Guangdong Shuanglin Bio-Pharmacy Co., Ltd.（China）
• Nanjing Xinbai Pharmaceutical Co., Ltd.（China）

结论与建议

Intravenous Immunoglobulin Market size was valued at USD 13.84 Billion in 2024 and is poised to grow from USD 14.85 Billion in 2025 to USD 26.1 Billion by 2033, growing at a CAGR of 7.3% during the forecast period (2026-2033).

The intravenous immunoglobulin (IVIG) market is experiencing significant growth driven by a range of factors, including an increasing aging population and a rise in immunodeficiency disorders. The broader acceptance of IVIG treatments and their application for off-label uses further enhance market demand. A notable rise in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) and associated bleeding issues intensifies this trend. Additionally, heightened healthcare investments are fostering this market's evolution. The increasing incidence of autoimmune diseases and various other pathological conditions also plays a crucial role in shaping the IVIG landscape, emphasizing the product's integral function in meeting diverse medical requirements and addressing the complexities of immunological health challenges.

Top-down and bottom-up approaches were used to estimate and validate the size of the Intravenous Immunoglobulin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Intravenous Immunoglobulin Market Segments Analysis

Global Intravenous Immunoglobulin Market is segmented by Product, Distribution Channel, Application and region. Based on Product, the market is segmented into IGG, IGA, IGM, IGE and IGD. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Specialty Pharmacies and Other. Based on Application, the market is segmented into Immunodeficiency diseases, CIDP, Hypogammaglobulinemia, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal motor neuropathy, ITP, Kawasaki disease, Guillain-Barre syndrome and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Intravenous Immunoglobulin Market

The growing adoption of intravenous immunoglobulin therapy as the primary treatment for a variety of rare immunological and neurological disorders, particularly primary immunodeficiency and related diseases, serves as a crucial factor driving the intravenous immunoglobulin market's growth. This widespread recognition of IVIG therapy as a leading option highlights its effectiveness and importance in addressing these complex health issues. As more healthcare providers and patients acknowledge the benefits of this treatment, the demand for intravenous immunoglobulin continues to rise, further solidifying its role in managing these challenging conditions and supporting market advancement.

Restraints in the Intravenous Immunoglobulin Market

The financial strain associated with diagnosing and treating demyelinating diseases poses a substantial challenge for the intravenous immunoglobulin market. The escalating costs associated with IVIG therapy are particularly concerning, as this treatment typically requires regular infusions every few weeks, leading to multiple sessions throughout the year. With the average cost of IVIG estimated at approximately USD 73.89 per gram, the cumulative expenses can reach around USD 10,000 annually. Such high costs serve as a significant obstacle to market growth, limiting accessibility for patients who need this essential therapy for managing their conditions effectively.

Market Trends of the Intravenous Immunoglobulin Market

The Intravenous Immunoglobulin (IVIG) market is experiencing a robust evolution driven by key trends that are redefining its growth potential. One prominent trend is the increasing adoption of IVIG for treating neurological disorders, which signifies a broadening of its applications beyond its conventional uses. Furthermore, the incorporation of personalized medicine into IVIG therapy represents a transformative shift, enabling more customized treatments tailored to individual patient profiles. Additionally, the rise of innovative immunomodulatory therapies is reshaping the market landscape, expanding therapeutic possibilities and enhancing patient outcomes, thereby propelling the overall demand and development of IVIG products.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Intravenous Immunoglobulin Market Size by Product & CAGR (2026-2033)

• Market Overview
• IGG
• IGA
• IGM
• IGE
• IGD

Global Intravenous Immunoglobulin Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies
• Other

Global Intravenous Immunoglobulin Market Size by Application & CAGR (2026-2033)

• Market Overview
• Immunodeficiency diseases
• CIDP
• Hypogammaglobulinemia
• Congenital AIDS
• Chronic Lymphocytic Leukemia
• Myasthenia Gravis
• Multifocal motor neuropathy
• ITP
• Kawasaki disease
• Guillain-Barre syndrome
• Others

Global Intravenous Immunoglobulin Market Size & CAGR (2026-2033)

• North America (Product, Distribution Channel, Application)
  • US
  • Canada
• Europe (Product, Distribution Channel, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Distribution Channel, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Distribution Channel, Application)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Distribution Channel, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion S.p.A (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio Products Laboratory Ltd. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biotest AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• China Biologic Products Holdings, Inc. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LFB SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai RAAS Blood Products Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ADMA Biologics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanquin Blood Supply Foundation (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kamada Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hualan Biological Engineering Inc. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Green Cross Corporation (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Serums and Vaccines Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guangdong Shuanglin Bio-Pharmacy Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nanjing Xinbai Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations